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1 Abstract  
Background: The use of herbal medicines in children and adolescents is continually on the 
rise. Contrary to popular belief, herbal products (HPs) are not always a safe alternative to 
conventional drugs and can cause a variety of adverse events such as severe and fatal allergic 
reactions. In regards to herbal medicine use in children, a recently published systematic 
review that searched PubMed, Embase, PsycINFO and AMED included 58 studies from 19 
countries and found overall herbal lifetime use to be between 0.8–85.5 % and 2.2–8.9 % for 
current use. Unlike most synthetically produced drugs, the adverse event profile of such 
“natural” preparations in children has rarely been studied. To this date, effective systems that 
monitor adverse drug events (ADRs) and long term side effects associated with HPs are 
either non-existent or still developing in many countries. Due to insufficient and inconsistent 
ADR reporting, little is known about the ADR spectrum of herbals in pediatric patients. 
Awareness of the potential of HPs to cause ADRs, particularly in children and adolescents, 
needs to be increased and reporting to national pharmacovigilance centers (PVCs) reinforced.  
Objectives: This project analyzed the worldwide adverse event data for herbal drugs related 
to hypersensitivity reactions as recorded in the WHO’s global individual case safety report 
(ICSR)  database VigiBase® between 1968 and August 2014, focusing on pediatric patients 
under the age of 18 years.  
Methods: From the original VigiBase® extract, only drugs with an herbal ATC code 
(HATC), classified as “suspect” with a certain, possible or probable causality assessment, a 
time of ADR onset of “0-1 day”, patient age less than 18 years and ADRs suggesting 
hypersensitivity, were included in this study. WHO-Art preferred terms indicating allergy 
were further divided into allergic and asthma-like. 
Results: 26,909 ICSRs relating to herbal drugs worldwide, accounting for a total of 237,496 
reported ADRs, comprised the original dataset. Of these 150 cases, representing 222 ADRs, 
met our study’s inclusion criteria. Out of 222 ADRs, 202 were classified as allergic and 20 as 
asthma-like. The most frequently reported WHO-ART terms in the allergic group were 
urticaria (22.1 %), rash (11.7 %) and anaphylactoid reaction (9.0 %). The most common 
reported terms of the asthma-like reactions were asthma (5.4 %) and bronchospasms (2.7 %). 
Mixed herbals were the most frequently reported suspect herbal causing almost equally as 
many allergic (60.9 %) as asthma-like reactions (70.0%). Anaphylactic shock was reported in 




Males (54 %) were slightly more affected than females (46 %). The majority of cases were 
reported in Germany (28 %), Sweden (15.3 %) and Thailand (11.3 %).  
Conclusion: Data analyzed as reported in VigiBase® showed that herbal medicines can 
cause severe hypersensitivity reactions and anaphylaxis in children and adolescents. To 
further optimize the usefulness of pharmacovigilance data and establish safer treatment 
regimens for pediatric patients, awareness of potential health threats through herbal 






















Unlike conventional medicines, herbal medicines do not undergo active clinical testing or 
post-marketing surveillance before or after marketing authorization. Therefore, for a newly 
introduced herbal preparation, the reporting of ADRs plays a critical role in determining its 
overall adverse event profile. For conventional medicines adverse event reporting primarily 
serves the purpose of determining long term ADRs that cannot be detected during the 
duration of clinical trials, as well as extremely rarely occurring adverse events of already 
established medicines.          
Contrary to popular belief, herbal remedies can cause severe ADRs and interactions 
with other herbals or medicines [1]. The lack of similar regulations for herbals that are 
already in place for conventional drugs, leave so called spontaneous reporting systems 
(SRSs) as the sole and principal source of adverse event data for herbal drugs. Furthermore, 
pharmacovigilance is a valuable tool in determining efficacy and interaction potential of 
herbal medicines, which due to the lack of pre-marketing studies would otherwise remain 
unidentified [2].  
Most research regarding drug safety in children has been conducted for prescription 
and non-prescription drugs, in particular vaccines, antidepressants, antipsychotics, other 
central nervous system (CNS) drugs, corticosteroids, antibiotics, antivirals and general 
anaesthetics [3]. Adverse events in children and adolescents associated with herbal medicines 
has only more recently been the subject of studies published in the literature [4-7].  
For both herbal and conventional medicines, the conduction of large scale clinical 
trials in children raises various ethical concerns and questions. The physiological changes 
that a child’s body undergoes until it reaches adulthood cause the pharmacodynamic and 
pharmacokinetic profile of a drug to differ from that in adults. Hence, paediatric patients 
require different dosage and treatment regimens and adverse events can vary in their 
manifestation [8-10]. Due to the lack of evidence based pharmacotherapy, paediatricians 
prescribe most medicines “off-label”. Off-label use is the prescription and administration of a 
medicine for an indication or population group it is not officially licensed for, or via a route 
of administration or dosage that has not been approved. The rate of off-label and unlicensed 
drug use in children was found to be 71.8 % in intensive care units (ICUs), 46.0 % on wards, 
33.0 % in outpatients and  10.8 % by general practitioners [11]. The U.S. FDA therefore 
emphasizes the importance of clinical trials in children in order to determine age dependent 




of drugs currently holding a license for the U.S. market have been approved for use in 
children [12]. 
With regard to herbal medicine use in paediatric patients, a recently published 
systematic review that searched PubMed, Embase, PsycINFO and AMED included 58 studies 
from 19 countries and found overall herbal lifetime use to be between 0.8–85.5 % and 2.2–
8.9 % for current use. Percentages representing lifetime use and current use for CAM 
(Complementary and Alternative Medicine) and homeopathy were analysed separately and 
ranged from 10.9–87.6 % and 0.8–39 % (lifetime) and 8–48.5 % and 1–14.3 % (current) 
respectively. Use of both herbal drugs and homeopathy in paediatric patients was highest in 
Germany [13].  
Overall, little evidence of the efficacy of most herbal medicines in children and adults 
exists. If positive results are reported these are usually attributed to a placebo effect rather 
than a pharmacological effect of the herbal preparation [14]. However, an example of an 
herbal that has recently been studied in a clinical trial and was found to be effective is Ginkgo 
biloba. The study by Shakibaei et al. found that G. biloba may have a positive additive effect 
in complementary therapy with methylphenidate to treat ADHD/hyperactivity disorder in 
children [15]. On the contrary, a randomized controlled trial by Salehi et al. showed that 
Ginkgo biloba monotherapy was not superior to methylphenidate in treating ADHD in 
children [16]. Contradicting evidence regarding the efficacy in children and adults exists for 
various herbals and most frequently depends on study design.  
Studies researching the relationship between herbal medicines and hypersensitivity 
reactions in children and adults are rare in the literature. A review by E. Ernst in 2003 
summarized the findings of serious ADRs in children and adults, based mostly on case series 
and case reports. Results showed serious ADRs such as intravascular haemolysis, 
hypertension, encephalitis, myocardial infarction or toxic hepatitis, have been caused by 
herbal medicines [4]. The most frequently reported serious ADRs were 149 cases of allergic 
reactions due to Eucalyptus. For all other reactions, sample sizes were much smaller and 
mostly consisted of case reports. It seems the frequency with which herbal remedies cause 
hypersensitivity reactions is significantly underestimated and underreported. An idea of how 
high the prevalence of allergic disorders in children is was found in the International Study of 
Asthma and Allergies in Childhood (ISAAC), which was conducted in 6- to 7-year-old 
Canadian children, of whom 10.8 % had allergic rhinoconjunctivitis symptoms, 18.2 % 
asthma symptoms, and 12 % eczema symptoms[17]. A systematic review by Gardiner et al. 




medicine use in children, found in decreasing order of frequency eucalyptus (n=12), camphor 
(n=10), fennel (n=6), jin bu huan (n=6), swanuri marili (n=6), kharchos suneli (n=6), tea tree 
(n=5), lavender (n=4), blue cohosh (n=3), buckthorn (n=3), liquorice(n=3), and garlic (n=3) 
to be the most  frequently reported herbals, primarily causing neurological and 
gastrointestinal symptoms [18]. Anaphylaxis was only reported in one case concerning a 
chamomile-containing enema, however, the review emphasized the need for improved 
reporting of case reports describing herbal induced adverse events. Overall, considering the 
seriousness and prevalence of allergy in pediatric patients in general and the underreporting 
of adverse event due to herbals, in particular in children and adolescents, lead us to analyze 
the available international ADR data indicating hypersensitivity reactions caused by herbal 
preparations in those less than 18 years of age.  
For adults, using electronic health care records in the form of spontaneous reports has 
previously shown to be a useful approach in the detection of ADRs [19]. The problem of 
underreporting of ADRs and the consequent lack of data is an even greater problem for 
children than adults, and more for herbals remedies than for conventional medicines. ADR 
reporting was found to occur least frequently in the age group of 5-19 year olds, and most 
frequently in 0- to 4-year-olds and 65- to 74-year-olds, with no significant difference in age 
distribution between low and high income level countries [20]. Polypharmacy, comorbidities, 
drug-drug or drug-herbal interactions between could explain an increased prevalence of 
ADRs in the elderly [21].   
Due to the limited data in the group of 5-19 year olds, other means of ADR detection 
in children such as patient interviews, information collected on hospital ward rounds, 
computerized records and case reports are employed [22]. Studies regarding 
pharmacovigilance in children have predominantly been published in North America, making 
up 64.8% of all studies included in a systematic review by Black et al. in 2015. Only 16.9% 
of the included studies used spontaneous reporting systems as ADR data source [3]. To the 
best of our knowledge, studies using data from spontaneous reporting systems that analyse 
worldwide adverse event data for hypersensitivity reactions in paediatric patients related to 
herbal medicines, do not currently exist in the literature. Therefore we decided to conducted 
as study investigating the prevalence of allergic reactions in children and adults associated 







The objective of this study was to analyze worldwide ADR reports of hypersensitivity 
reactions in children under the age of 18 related to herbal medicines between 1968 and 
August 2014. The scope of this Master’s thesis is to identify frequently reported herbals 
associated with hypersensitivity reactions in children and adolescents as reported in 
VigiBase®. Analysis of the data aimed to provide information about herbal medicines most 
commonly related to allergic and asthma-like symptoms, as well as factors such as gender, 



















4 Theoretical part 
4.1 Global pharmacovigilance systems  
Pharmacovigilance (PV), also known as drug safety, is a term used in the pharmacological 
sciences and describes the process of monitoring and preventing adverse drug reactions 
(ADRs). The official definition of the WHO of pharmacovigilance is “a science and activities 
relating to the detection, assessment, understanding and prevention of adverse effects or any 
other drug-related problem” [23]. An adverse drug reaction can be described as “any 
undesirable effect of a drug beyond its anticipated therapeutic effects occurring during 
clinical use” [24]. According to the WHO, an ADR is “a response to a drug which is noxious 
and unintended, and which occurs at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modifications of physiological function” [25]. An 
ADR is distinguished from a toxic reaction, which occurs at above therapeutic 
concentrations, and a side effect, which is dose-dependent and not associated with the 
therapeutic effect of a drug. Compared to ADRs, side effects can be beneficial in nature e.g. 
some antihistamines also have antiemetic and sedative properties that can reduce nausea and 
help with falling asleep. The term “adverse effects” or “adverse drug reaction” on the other 
side implies solely undesirable effects. The WHO ADR definition therefore excludes 
reactions due to contaminants which are often found in herbal products [26] and are the main 
focus of this study. 
Between 1950-1960, thalidomide, back then known as Contergan, was heavily used as 
a medication to treat morning-sickness in pregnant women, particularly in Germany. As a 
result of its teratogenic effect, an estimated 10,000 children in 46 countries were born with 
congenital abnormalities and malformations of the limbs [27]. In response to what is now 
known as the biggest post-marketing tragedy of the pharmaceutical industry in the 20th 
century and to prevent such disasters from recurring, the WHO initiated its international ADR 
monitoring program in 1968 with the goal of creating a global ADR database. Today the 
WHO’s global individual case safety report (ICSR) database, VigiBase®, is located at the 
UMC (Upsalla monitoring centre) in Sweden [28]. VigiBase® is a spontaneous reporting 
system (SRS) for individual case safety reports (ICSRs) with the purpose to detect drug 
safety signals. Since the foundation of the program, the number of participating nations has 
continually been on the rise, and as of December 2014, counts 120 member countries and 29 




reporting systems [29, 30]. In 2013 the leading country in terms of ADR reports per 1mio 
inhabitants was Singapore, followed by the U.S. [21]. Currently, VigiBase® holds a total of 
over 10 million ICSRs that have been reported by member countries the start of the operation 
of the international pharmacovigilance program in 1968 [31].  
Apart from the WHO, many countries started establishing their own ADR databases. 
In the United States the Adverse Event Reporting System (AERS) of the US Food and Drug 
Administration (FDA) implemented the reporting of ADRs under the name of the MedWatch 
program [32]. In the U.K. the GPRD (General Practitioners Research Database) is operated 
by the National Institute for Health Research (NIHR) and the Medicines and Healthcare 
products Regulatory Agency (MHRA) [33], and in Spain adverse drug reactions are reported 
to the Sistema Español de Farmacovigilancia (SEFV) (Spanish Pharmacovigilance System) 
[34]. However, the problem of underreporting of adverse events, in particular in relation to 
herbals, is not an issue of only a few nations but a global challenge. A good example 
explaining the reason for the lack of evidence and studies for herbal medicines is TCM 
(traditional Chinese medicine). Herbals are one of the fundamental therapy approaches used 
in TCM, along with acupuncture, which has been gaining increasing popularity in Western 
countries such as Europe and the U.S. In the United States the approval of acupuncture 
needles as medical devices by the U.S. Food and Drug Administration (FDA) [9], lead to the 
cost of acupuncture being covered by some insurance policies. However, traditionally used 
Chinese herbals are viewed and regulated as dietary supplements and the cost is not covered 
by most insurance providers. This conflict of interest between government funding for drug 
research and the questionable categorization of herbal remedies as supplements may 
contribute to the gap between scientific evidence-based medicine and human use-based 
practice.  
Dietary supplements according to the FDA are “safe until proven unsafe”, where the 
evidence to disprove their safety can only be supplied through case reports or retrospective 
studies. On the contrary, conventional medicines are subject to strict distribution criteria and 
undergo vigorous testing during all clinical trial phases, before market authorization is 
granted. Sometimes ADRs only occur decades after sales and marketing of a medicinal 
product. Hence, in PV the discovery of previously unknown and serious ADRs through signal 
detection is of greatest interest [21]. The goal of SRSs is to generate ADR signals that can 
ultimately lead to a drug being withdrawn from the market. One of the most commonly used 
examples to illustrate the importance of SRSs is the market withdrawal of Rofecoxib 




drug, was withdrawn due to an increased risk of cardiovascular morbidity through stroke 
and/or heart attack. Cerivastatin, a cholesterol lowering agent, showed repeatedly more cases 
of rhabdomyolysis than for other members of the statin group. However, not can only rare or 
long term ADRs be detected through SRSs but adverse events that occur more frequently. 
These can remain undiscovered during the testing phases as trials can fail to represent the 
actual future patient population in size or exclude the presence of certain co-morbidities [36].  
Before the establishment of SRSs in 1960, pharmacovigilance data was collected 
through phase VI clinical trials sponsored by the industry or prospective clinical registries. 
Today SRSs depend on patients, health care workers and pharmaceutical companies to report 
adverse events for both conventional and herbal medicines. Since health care practitioners are 
not legally entitled to report ADRs outside of clinical trials, the entire PV system relies on 
medical staff reporting ADRs to meet their own personal ethical and moral obligations. 
Furthermore, many health care professionals forward patient reports long after the occurrence 
of an ADR, sometimes because of lack of time and inconvenience of the process. This delay 
in information transfer to national and regional centres further defers the data analysis 
process at the WHO and possibly protracts signal detection. A signal as defined by the WHO 
is “reported information on a possible causal relationship between an adverse event and a 
drug, the relationship being unknown or incompletely documented previously”[37]. The 
slowness and incompleteness of SRSs is their main drawback [36]. The inconsistency that 
accompanies non-mandatory reporting regulations in most countries results in underreporting 
and underutilization of pharmacovigilance as a tool for ADR detection and post-marketing 
surveillance [36] because data is submitted voluntarily and no systematic monitoring strategy 
is in place [32]. Data mining of electronic medical record (EMR) systems have emerged as an 
alternative option to phase IV trials and clinical registries [38]. There are various statistical 
measures that are used in signal detection from EMR data that along with biostatistical 









4.2 Adverse event reporting  
Different countries use different 
pharmacovigilance systems. Since 
we are using data extracted from 
VigiBase® in this study, the systems 
used by all member countriess of the 
WHO’s international ICSR 
monitoring program will serve as an 
example to illustrate the process of 
adverse event reporting. All member 
countries and their national and 
regional pharmacovigilance centres 
can obtain access to VigiFlow®. 
VigiFlow® is “a complete Individual 
Case Safety Report (ICSR) 
management system for 
pharmacovigilance (PV) at a national 
level”[39] and can be used by any 
country that is part of the WHO 
international pharmacovigilance 
program. Once a national or regional 
PV centre receives an ADR report 
from e.g. a doctor or pharmacist, the 
data is entered into VigiFlow®. ADR 
terminology is coded in either 
MedDRA or WHO-ART and ICSRs 
are compatible with the international 
standard ICH-E2B format. Herbal medicine are assigned an herbal ATC code (HATC) [40].   
Once entered into VigiFlow®, the information is forwarded for further assessment to the 
central national PV centre and analysed for completeness. The national centre verifies the 
information in the ICSR, including the causality assessment, and reports are forwarded to the 
UMC (Uppsala Monitoring Centre) and stored in VigiBase®. VigiBase® is the WHO’s 
Fig 1 Flow of ICSRs 
Reports arriving at the WHO are coded in E2B format, a 
messaging standard used to send and receive ADR reports in 
ICSR format. Source: WHO-UMC. VigiFlow® The 





international ICSR database. ADRs can directly be reported to national or regional PV 
centres by pharmaceutical companies, health care professionals and in some countries such as 
the U.S. also by consumers [33]. Figure 1 shows a diagram of the ICSR report flow [39]. The 
data mining tool VigiLyze™ can be used to search and analyse reports stored in VigiBase® 
[41]. The WHO also provides a statistical analysis tool called VigiMine. All drug-ADR pairs 
as reported in VigiBase® can be statistically analysed according to various criteria. 
Stratification by age, gender, country and year of reporting is also possible [42]. Each case 
concerns a single patient and can have only one suspect drug but more than one reported 
ADR. . If an interaction was suspected, multiple drugs can be coded as interacting. 
Despite the WHO’s international ADR monitoring program, collaborating countries 
vary in their reporting strategy. In some countries, for example Sweden, health care providers 
are compelled to report any ADRs to the national pharmacovigilance centres within the first 
two years after market authorization and particularly serious, rare and unknown ADRs at any 
time after approval  [43]. However, generally there is no legal obligation in most countries 
that requires medical staff to report ADRs to a drug safety agency.  
Guo et al showed in their study that in China serious and less serious ADRs are 
reported equally frequent, whereas in the U.K. reporting of serious ADRs is actively being 
encouraged. As a result a higher proportion of ADRs in the U.K. is classified as such, not 
because more serious ADRs occur in the United Kingdom than in China. The study also 
discussed the varying proportion of reporter type by country. In some countries 
pharmaceutical companies provide the main source of ADR reports, in others health care 
professionals and patients primarily take on this role. This shows that there is a substantial 
difference in awareness of the public by country to be able to report ADRs [21]  and the need 
to educate people about pharmacovigilance.  





4.3 Causality assessment 
Spontaneous ICSRs are assed according to their 
causality between the reported ADR(s) and drug(s). 
The WHO has defined certain criteria that a report 
has to meet to be classified as belonging to one of 
the 6 assessment groups as shown in Table 1 [26]. 
To be classified as certain, a positive re-challenge 
must have occurred, i.e. the reported ADR must 
recur after repeated administration of the suspect 
herbal, and the temporal relationship needs to be 
plausible. Certain differs from the definition of 
probable/likely, which also requires a temporal 
connection but only a positive de-challenge, 
meaning the ADR subsided after discontinuation of 
the drug. Lastly, for a case to be defined as possible, 
the most important criteria is an existing temporal 
relationship between drug intake and occurrence of 
an ADR. Due to missing information from the 
primary reporter, many cases can only be classified 
as possible. Pharmacovigilance officers at regional 
and national centres will often follow up with the 
primary reporter to obtain sufficient information 
and provide the most accurate causality assessment 
as possible. An example of a case where even a 
positive rechallenge will not lead to a certain 
causality assessment is the occurrence of 
thromboembolic disorders with combined oral 
contraceptives (COCs). The reason for this is that 
there is a certain background incidence of e.g. 
thromboembolisms in women who do not take 
COCs. Therefore, in such cases the causality can 
never be classified as certain.	  
 
Certain	  
●	   A	   clinical	   event,	   including	   a	   laboratory	   test	  
abnormality,	  that	  occurs	   in	  a	  plausible	  time	  relation	  
to	   drug	   administration,	   and	   which	   cannot	   be	  
explained	   by	   concurrent	   disease	   or	   other	   drugs	   or	  
chemicals	  
●	   The	   response	   to	   withdrawal	   of	   the	   drug	  
(dechallenge)	  should	  be	  clinically	  plausible	  
●	  The	  event	  must	  be	  definitive	  pharmacologically	  or	  
phenomenologically,	  using	  a	  satisfactory	  rechallenge	  
procedure	  if	  necessary	  
	  
Probable/likely	  
●	   A	   clinical	   event,	   including	   a	   laboratory	   test	  
abnormality,	   with	   a	   reasonable	   time	   relation	   to	  
administration	  of	  the	  drug,	  unlikely	  to	  be	  attributed	  
to	   concurrent	   disease	   or	   other	   drugs	   or	   chemicals,	  
and	   which	   follows	   a	   clinically	   reasonable	   response	  
on	  withdrawal	  (dechallenge)	  




●	   A	   clinical	   event,	   including	   a	   laboratory	   test	  
abnormality,	   with	   a	   reasonable	   time	   relation	   to	  
administration	  of	   the	  drug,	  but	  which	  could	  also	  be	  
explained	   by	   concurrent	   disease	   or	   other	   drugs	   or	  
chemicals	  




●	   A	   clinical	   event,	   including	   a	   laboratory	   test	  
abnormality,	   with	   a	   temporal	   relation	   to	  
administration	   of	   the	   drug,	   which	   makes	   a	   causal	  
relation	   improbable,	   and	   in	   which	   other	   drugs,	  




●	   A	   clinical	   event,	   including	   a	   laboratory	   test	  
abnormality,	  reported	  as	  an	  adverse	  reaction,	  about	  
which	   more	   data	   are	   essential	   for	   a	   proper	  




●	   A	   report	   suggesting	   an	   adverse	   reaction	   that	  
cannot	  be	  judged,	  because	  information	  is	  insufficient	  
or	   contradictory	   and	   cannot	   be	   supplemented	   or	  
verified	  
Table1:	  Causality	   assessment	   of	   suspected	   adverse	  
drug	   reactions.	   Source:	  Adapted	   from	  Edwards	   IR,	  
Aronson	   JK.	   Adverse	   drug	   reactions:	   definitions,	  






4.4 Safety of herbal medicines	  
The annual use of herbal medicines in the general population has been estimated to lie 
between 20-54 % according to different population studies [44]. Impurity, contamination and 
counterfeit products are a major concern for children, adolescents and adults alike. Use of 
complementary and alternative medicines (CAM) such as herbal preparations are also 
frequently used by pregnant women, and most women self-treat without consultation of their 
doctor [45]. For the same reasons adults may choose to use herbal supplements, parents might 
be inclined to give them to their children. Ernst and Hung summarized in their review of 73 
articles the following expectations that users of complementary and alternative medicines had 
(in order of highest to lowest reported response): Hope to influence the natural history of the 
disease; disease prevention and health/general well-being promotion; fewer side effects; 
being in control over one's health; symptom relief; boosting the immune system; emotional 
support; holistic care; improving quality of life; relief of side effects of conventional 
medicine; good therapeutic relationship; obtaining information; coping better with illness; 
supporting the natural healing process; and availability of treatment [46]. The third most 
frequent response was “fewer side effects” and the tenth “relief of side effects of 
conventional medicines”. This shows how widespread the misconception is that herbal 
medicines are a health risk free alternative to standard pharmacotherapy. Many parents 
naively believe that herbal remedies do not contain “chemicals”. However, little data 
regarding the safety profile of herbal medicines exist [44]. By assuming to choose a better 
alternative for their children, parents can actually harm their children by delaying or replacing 
conventional medical treatment [1, 47]. Even deaths due to CAM use in favour of 
conventional medicines in children have been reported [5].	  
Unlike conventional medicines, herbal products can easily be acquired in pharmacies, 
supermarkets, drugstores and on the internet. Due to less strict regulations regarding the 
production of herbal products, quality of the preparations is frequently an issue. Batches may 
vary in concentration and composition or contain contaminants [48]. Counterfeit products 
that can easily be acquired on the internet pose another threat to consumers. Presence of 
impurities as well as dubiety about actual ingredients, potency and purity are a concern and 
may have negative health implications [44]. Hepatotoxicity is a frequently studied serious 
adverse reaction associated with herbal drug use. Examples of single ingredient herbals that 
have been shown to cause liver damage are different Chinese herbals, Teucrium species and 




weight loss [48]. Alongside TCM, Indian Ayurvedic medicine also use predominantly herbal 
remedies. A study by Saper et al. found that 14 out of 70 selected ayurvedic herbals contained 
lead, mercury and/or arsenic. Some of the tested herbals were specifically designated for 
paediatric patients and contained a 2 to 3 fold higher mercury content than references doses 
suggested by the EPA (Environmental Protection Agency); at least 55 cases of heavy metal 
intoxication associated with ayurvedic herbals in children and adults have been reported in 
the U.S. and elsewhere since 1978 [49]. Examples of herbals for which severe toxicities or 
interactions are known are St. John’s wort, Kava-kava, Wormwood, Nutmeg, Valerian, 
Catnip, Ginseng, Ginkgo biloba, Comfrey, Blue cohosh, Pennyroyal oil from Mentha 
pulegium, apricot kernels, podophyllin from Podophyllum peltatum, Kan-mokutsu 
(Aristolochia manshuriensis) and Aristolochia fangchi, Chuen-lin (Coptis chinensus or C. 
japonicum) and yin-chen (Artemisia scoparia) or Danshen (Salvia miltiorrhiza) [6]. 
An example of a serious but not allergic reaction gives the study by Halicioglu et al. 
who reported two cases of generalized tonic-clonic seizures in an infant and a toddler after 
oral intake of sage oil (Salvia officinalis). Substances contained in sage oil such as 1,8-
cineole, camphor, a-thujone, b-thujone, borneol, and viridiflorol have been shown to have 
epileptogenic properties [50]. This is a good example of how a plant based medicinal product 
that would be considered safe by consumers and parents can unexpectedly provoke severe 















4.5 Hypersensitivity reactions associated with herbal medicines 
Initially classified by Coombs and Gell in 1963, immediate allergic reactions, also known as 
type A or type I allergic reactions, refer to the IgE mediated process that causes the onset of 
symptoms soon after exposure to an allergen [51]. Type I reactions are characterized by 
rhinitis, headache, dermatitis (hives), and/or anaphylactic shock whereas Type 4 allergic 
reactions are known as delayed hypersensitivity and are associated with contact dermatitis 
[52]. Hard to distinguish from anaphylactic reactions are anaphylactoid reactions, which are 
not governed by immunological processes but due to mast cell degranulation. Anaphylactoid 
is now considered to be an outdated term by the World Allergy Organisation and the term 
non-allergic anaphylaxis or non-immune anaphylaxis should be used instead [53]. 
Anaphylaxis in childhood is most commonly triggered by hypersensitivity to allergens 
contained in food [54]. Wheat, milk, eggs, fish, soy and peanuts most frequently lead to an 
anaphylactic shock in children and adolescents [55]. Herbal medicine use is not just 
increasing amongst the adult population but also in adolescents. Results of an online survey 
found that 41% of 520 adolescents stated they had used herbal or green tea, zinc, echinacea or 
echinacea/goldenseal, ginseng, ginger, ginkgo biloba, soy supplements, omega 3 fatty acids 
or fish oil, creatine, weight loss supplements, St. John’s wort, valerian, ephedra, or feverfew 
before [56].  
Data regarding hypersensitivity reactions associated with herbal drug use in children 
is particularly rare in the literature [56] and case reports are the main source of information. 
More evidence is available regarding the occurrence of allergic reactions in the general 
population. For example, a study by Wechwithan et al. previously reported the occurrence of 
allergic reaction such as anaphylaxis, angioedema, urticaria and facial oedema due to 
different Thai herbal preparations [57]. In the study analysis of all reports in the Thai ADR 
database between 2002 and 2013 yielded 502 reports of ADRs associated with Thai 
traditional medicines (TTM). The highest percentage of ADRs classified as serious was 
reported for Andrographis paniculata (24.6 %), Derris scandens Benth (19.2 %) and 
Curcuma longa Linn. (14.6 %). Six reports of anaphylactic shock, 47 of urticaria and 11 of 
facial oedema were reported for A. paniculata. Five reports of angioedema were found for D. 
scandens whereas C. longa (Tumeric) was associated with gastrointestinal symptoms such as 
nausea, vomiting, diarrhoea or dizziness.  
Another example of an herbal induced hypersensitivity reaction is a case report by 




suffering from facial oedema after taking Echinaforce®, an herb and root extract from 
Echinacea purpurae. After extensive testing a positive reaction to sesquiterpene lactones was 
detected, which are commonly found in the Asteraceae/ Compositae family [58]. Cross 
reactions within the Asteracea family are known to occur and result in hypersensitivity type 1 
reactions when other plants of this family are used [52]. Cases of anaphylaxis for Echinacea 
purpurae have been reported, but are also known to occur for other members of the Asteracea 
family that are commonly used such as chamomile (Chamaemelum nobile) and milk thistle 
(Silybum marianum); long-term use of Echinacea, Evening primrose (genus Oenothera) and 
Ginkgo are associated with allergy [52]. 
With regards to Chinese herbal medicines Ji et al. report cases of sever and fatal 
anaphylaxis associated with the use of nine different Chinese herbal injections used to treat 
upper respiratory tract infectionsor the common cold.Out of 150 cases, 27 concerned children 
under the age of 12, of which 6 were lethal. Injections used contained one or more herbal 
ingredient and included Shuanghuanglian (Scutellaria baicalensis, Flos lonicerae, Forsythia 
suspense), Qingkailing (Cholic acid, Conchamargaritifera, Hyodesoxycholic acid, Bubalus 
bubalis, Gardenia jasminoides, Isatis indigotica, Scutallaria baicalensis, Flos lonicerae), 
Chaihu (Radix Bupleuri), Banlangen (Isatis indigotica), Chuanhuning (Androrgraphis 
paniculata, Nees leaf extract, potassium sodium dehydroandroan drographolide succinate), 
and Yuxingcao (Houttuynia cordata); allergic reactions constitute 44.6-50.49 % of all 
reported ADRs for Chinese erbal injections  [59].    
The described studies are just examples of studies that have been published in the 
literature and comprise the current evidence base. Likely most allergic reactions and cases of 
anaphylactic shock have never been reported in first place and the actual extent of 
hypersensitivity reactions in children associated with herbal medicines remains significantly 
underrepresented and underestimated. One of the largest challenges remains changing the 
common misconception people have that herbal medicines are “natural” and “safer” than 










4.6 Cost of adverse drug reactions 
Not only impact drug associated adverse events, for herbal and conventional medicines alike, 
patient health but required medical treatments needed for recovery require to use health care 
funds for health problems that could have potentially been avoided altogether. Overall, cost 
and adverse events associated with herbal medicine use in children are infrequently discussed 
in the literature [61] but some studies show that they impose substantial financial expenses on 
health care systems worldwide. The importance of post marketing surveillance becomes 
evident considering that, depending on the study, about 6.2 % off all hospital admission are 
attributed to adverse drug reactions [24, 32, 62]. Apart from the cost of treatment, patients 
seeking immediate medical attention at emergency departments further contribute to the 
problem of long waits at ERs that are already being operated at full capacity. Investigating 
this problem, Patel et al.  found in their study that approximately 28 % of all visits to 
emergency departments are due to ADRs, illustrating the impact on the health care system 
[63]. Looking at fatal outcomes, a study by Juntti-Patinen and Neuvonen, found that 5% of all 
deaths at a Helsinki hospital were probably or certainly due to an adverse drug reaction. 
However, most of the patients were severely ill and treated with drugs known to have 
frequent and serious side effects [62]. 
In the UK alone up to 50 % of people are thought to have used an herbal medicinal 
product at least once in their life [64]. In 2009, global expenditures on herbals amounted to 
62 billion dollars [65]. In relation to herbal remedies, a study by Engebretsen et  al. showed 
that approximately 5-10 % of patient visits to dermatological clinics are related to plants and 
plant products [58]. Kimland et al report that 5 % of hospital admissions of children are 
related to ADRs [43] whereas results of a review by Clavenna and Bonati found that 1.8% of 
hospital admission in children were caused by ADRs [66]. An idea of just how much adverse 
drug reactions in paediatric patients can cost the health care system per year showed a 
prospective observational cohort study by Kunac et al. in 2009. The authors found that the 
annual cost of 67 ADRs, of which 38 could have been prevented, added up to 235, 214 New 
Zealand dollar (2002 values), with roughly two thirds being attributed to preventable ADRs 
($NZ 148, 287) [67]. This shows that many adverse events could be prevented and the 






5 Methods  
5.1 Data sources 
The WHO’s global individual case safety report (ICSR)  database VigiBase® reporting 
system counted over 10 million reports as of April 2015 [31]. In this study, a data extract 
provided by the Uppsala Monitoring Center (UMC) in Sweden for the period of the start of 
the WHO’s international pharmacovigilance program in 1968 and August 2014 was used. 
The UMC manages the WHO’s global individual case safety report (ICSR) database 
VigiBase®.  
 
5.2 Herbal medicine definition 
This study uses the WHO definition of herbal medicines: “Herbal medicines include herbs, 
herbal materials, herbal preparations and finished herbal products that contain as active 
ingredients parts of plants, or other plant materials, or combinations” [68]. All substances of 
natural origin in VigiBase® are grouped by HATC (Herbal Anatomical-Therapeutic-
Chemical) codes [69]. 
 
5.3 Case selection  
Patient age was limited to < 18 years and time of ADR onset to ≤ 1 day to distinguish reports 
of immediate hypersensitivity (Type I) reactions from delayed onset hypersensitivity 
reactions (Type IV). Substances not classified as suspect or with non-HATC codes were 
omitted. WHO-ART preferred terms indicating to be a symptom of an immediate 
hypersensitivity reaction were selected manually (WHO Drug Dictionary Enhanced (Version 
June 1, 2014). Reaction terms less suggestive of hypersensitivity or more likely to have a 
different etiology than the suspect herbal such as cough, dyspnoea, larynx pain and pruritus 
ani or genital were excluded from the reaction terms. GIT symptoms were excluded 
altogether. Terms were divided into two groups, those considered as allergic and those as 
asthma-like, where WHO-ART preferred terms asthma, stridor and/or bronchospasm 







Table 2 Example of manually selected WHO-ART terms indicating immediate 
hypersensitivity reactions 




Allergy Asthma* Flushing Oedema pharynx Stridor* 
Anaphylactic 


















* reactions terms classified as asthma-like 
5.4 Causality assessment 
Only Cases where the relationship between an herbal and an adverse drug reaction was 
classified according to WHO standardised case causality assessment as either certain, 
probable and possible [70] were included in this study. Figure 2 summarizes the selection 
process. 
 
5.5 Statistical analysis 
Data analysis was carried out using the statistical data analysis software STATA® and 
descriptive statistics. 
 
5.6 Confounders          
Confounders that may have influenced study results are primarily co-morbidities and co-
medications. Children with co-morbidities such as cystic fibrosis, attention deficit disorder, 
asthma, atopic dermatitis, allergic rhinitis, cancer, inflammatory bowel disease, and 
rheumatoid arthritis have been shown to use Chinese herbal medicine, Ginkgo, Echinacea, 
and St. John’s wort more frequently than children who are not affected by these diseases [56]. 
Likewise, co-medications may confound the data since a suspect herbal can no longer be 
considered the only possible source of a reported hypersensitivity reaction. However, analysis 
of the presence of co-morbidities and intake of co-medications is beyond the scope of this 




they do not belong to the four minimum criteria (Reporter ID, patient, drug, ADR) needed to 




Figure 2:     Flowchart depicting case selection process and exclusion/inclusion criteria. 
     1Herbals coded as “concomitant”, “interacting”, “null” and “not converted” were not included in the study cohort 
     2Manual selection, classification and revision of ADRs indicating high specificity regarding allergic reactions 
     3Calculation of latency time in STATA® based on “onset date” (of ADR) and “start date” (of herbal drug) 
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6 Results  
This study used a data extract of VigiBase® [from 1968] to August 2014, which contains 
26,909 unique ICSRs relating to herbal medicines from 42 different countries. The total 
number of adverse drug reactions was 237,496 (lines), coded according to the WHO Drug 
Dictionary Enhanced (Version June 1, 2014) in WHO-ART adverse reaction terminology. 
The final cohort in our study consists of 150 ICSRs with 222 ADRs indicative of an allergic 
reaction following the use of one or more herbal medicines in children under 18 years of age. 
This represents 0.56 % of all ICSRs and 0.09 % of ADRs of the original VigiBase® extract.  
 
6.1. Reports by gender 
From the total data set, 150 cases met our inclusion criteria. Gender was reported in all 150 
cases, with male paediatric patients accounting for 54 % and females for 46 % of the study 
population (Table 3). Overall, the average number of ADRs reported per case by gender was 
1.5 for both males and females.  The three most frequently reported ADRs by gender were 
urticaria, rash and anaphylactoid reaction (Figure 3) of which 63.3%, 42.3% and 70.0 % 
occurred in males and 36.7 %, 57.7 % and 30.0 % in females respectively. 
 
Table 3     Cases reports by gender (n=150) 
Gender  Frequency Per cent %1 Cumulative %    
Male  81  54  54 
Female  69  46  100  
Total               150   100   




Figure 3 Occurrence of ADRs by Gender (n=222) 
Overall, 81 male and 69 female pediatric patients were included in this study for which 120 
and 102 ADRs were reported respectively. More cases of males suffering from urticaria and 
anaphylactoid reaction were reported. Females were also more frequently affected by rash. 
Two thirds of case with anaphylactic shock occurred in females.  
 
 
6.2 Reports by age 
 
 
 Figure 4 Reports of allergic ADRs to herbals by age group (n=222) 
 
Patient age with the highest frequency of reported allergic ADRs to herbals was age 16; only 
one report exists for age 0-1. The mean age was 8.5 years and the standard deviation ± 3.9 
years. Numbers of ICSRs increased with age and most cases occurred in the group age 13-17 




6.3 Geographical distribution 
All 150 reports meeting our inclusion criteria were reported in 23 countries with 14 being in 
Europe, 4 in Asia, 2 in Oceania, 2 in North America and 1 in South America. The majority of 
ICSRs came from Germany (28 %), followed by Sweden (15.3 %) and Thailand (11.3 %), 
representing over half of all cases included in this study (54.7 %) (Table 4). 
 
Table 4 Occurrence of allergic ADRs related to herbal drugs by country (n=222) 
Country  Frequency  Per cent %  Cumulative % 
Germany         42          28.0         28.0 
Sweden            23          15.3         43.3 
Thailand           17          11.3         54.7 
Australia            9           6.0         60.7 
Spain             8           5.3         66.0 
Denmark            7           4.7         70.7 
Switzerland           7           4.7         75.3 
Norway            6           4.0         79.3 
Austria             5           3.3         82.7 
Korea, Republic of    4           2.7         85.3 
Malaysia            3           2.0         87.3 
Netherlands            3           2.0         89.3 
Ukraine            3           2.0         91.3 
Cuba             2           1.3         92.7 
New Zealand            2           1.3         94.0 
United Kingdom         2           1.3         95.3 
Croatia             1           0.7         96.0 
Czech Republic           1           0.7         96.7 
Indonesia            1           0.7         97.3 
Mexico             1           0.7         98.0 
Peru             1           0.7         98.7 
Portugal            1           0.7         99.3 
Slovakia            1           0.7         100.00 










6.4 Annual distribution 
 
 
Figure 5 Number of ADRs reported per year (n=222) 
Analysis of reports by year of reporting showed that no report that met our inclusion criteria 
was reported before 1986. The majority of 150 cases included in this study were reported 
after 2008. A significant gap can be observed in 2012 (Figure 5). 
 
6.5 Causality assessment  
All cases with a WHO causality assessment category of certain, probable and possible were 
included, with less than one fifth indicating a definite relationship between an ADR and a 
herbal medicine (Table 5). Due to rounding, percentages may not always appear to add up to 
100 %. 
Table 5 ADRs by causality assessment (n=222) 
Causality assessment       Frequency    Percent %1      Cumulative % 
Possible   92  41.4  41.4 
Probable   91       41.0       82.4 
Certain            39       17.6        100.0 
Total           222      100.0 




6.6 Adverse drug reactions 
The total number of reported ADRs divided into allergic and asthma-like in our study 
population of 150 cases was 222, representing 1.48 reported ADRs per unique case report ID 
and suspect herbal. Allergic reactions accounted for 91.0% of all ADRs, asthma-like 
reactions for 9.0% of all ADRs (Table 6). 
 
Table 6 Type of ADR (n=222)  
ADR type       Frequency    Percent %1      Cumulative % 
Allergic          202       91.0        91.0 
Asthma-like   20       9.0        100.0 
Total         222      100.0 
1 Percentage of ADR type of 150 cases  
 
The most frequently reported ADRs were urticaria (22.1 %), rash (11.7 %), anaphylactoid 
reaction (9.0 %) and rash erythematous (7.7 %), accounting for 56.8 % of all reported ADRs 
(Table 7). About one third of ADRs (80 of all 222 ADRs) were reported as serious. It should 
be noted that this is not a complete list of the manually selected reaction terms but only those 
for which ADRs were reported.  
 
Table 7 Most frequently reported WHO-ART preferred terms (n=150) 
WHO-ART PT       Frequency      Percent %1      Cumulative % 
Urticaria            49         22.1        22.1 
Rash            26         11.7        33.8 
Anaphylactoid reaction          20         9.0        42.8 
Rash erythematous          17         7.7        50.5 
Anaphylactic reaction          16         7.2        57.7 
Allergic reaction           12         5.4        63.1 
Anaphylactic shock          12         5.4        68.5 
Asthma2            12         5.4        73.9 
Oedema mouth           12         5.4        79.3 
Bronchospasm2   6          2.7        82.0 
Angioedema             5          2.3        84.2 
Dermatitis            5          2.3        86.5 
Face oedema             4          1.8        88.3 
Flushing             4          1.8        90.1 
Oedema periorbital            4          1.8        91.9 
Larynx oedema            3          1.4        93.2 
Rash maculo-papular           3          1.4        94.6 




Oedema pharynx            2          0.9        96.4 
Stridor2              2          0.9        97.3 
Tongue oedema            2          0.9        98.2 
Allergy              1          0.5        98.7 
Erythema multiforme            1          0.5        99.1 
Skin reaction localized            1          0.5        99.6 
Urticaria acute             1          0.5        100.0 
Total    222  100.0 
1 Percentage of ADR by case causality 
2 Reaction terms classified as asthma-like  
 
 
6.7 Suspect herbals 
The most commonly reported suspect herbals were mixed herbals (61.7 %), Phleum pratense 
(13.1 %), also known as Timothy-grass, and Hedera helix (7.2 %), the common Ivy, all 
together contributing to 82.0 % of all reported ADRs in this study (Table 8). 
 
Table 8 Suspect herbals associated with all ADRs (n=222) 
Herbal high level classification Frequency    Percent %1      Cumulative % 
Mixed herbals           137        61.7        61.7 
Phleum pratense            29         13.1        74.8 
Hedera helix             16         7.2        82.0 
Echinacea purpurea             6          2.7        84.7 
Andrographis paniculata           5          2.3        86.9 
Thymus vulgaris             4          1.8        88.7 
Artemisia vulgaris             3          1.4        90.1 
Calendula officinalis            2          0.9        91.0 
Carica papaya             2          0.9        91.9 
Hamamelis virginiana            2          0.9        92.8 
Matricaria recutita              2          0.9        93.7 
Senna alata              2          0.9        94.6 
Arachis hypogaea             1          0.5        95.1 
Arctostaphylos uva-ursi           1          0.5        95.5 
Arnica montana             1          0.5        96.0 
Atropa belladonna             1          0.5        96.4 
Avena sativa              1          0.5        96.9 
Eucalyptus globulus             1          0.5        97.3 
Melaleuca alternifolia             1          0.5        97.8 
Mentha x piperita             1          0.5        98.2 
Papaver somniferum            1          0.5        98.7 
Pelargonium sidoides             1          0.5        99.1 




Symphytum officinale             1          0.5        100.0 
Total             222       100.0 
1 Percentage of suspect herbals associated with allergic and asthma-like ADRs (n=222) 
 
Of suspect herbals associated with allergic reactions 60.9 % were mixed herbals, 12.4 % 
Phleum pratense and 7.9 % Hedera helix (Table 9). Similarly, asthma-like reactions were 
mostly associated with mixed herbals (70.0 %) and Phleum pratense (20.0 %) (Table 10).  
 
Table 9 Reported suspect herbal associated with allergic reactions (n=202) 
Suspect herbal   Frequency    Percent %1      Cumulative % 
Mixed herbals           123        60.9        60.9 
Phleum pratense           25         12.4        73.3 
Hedera helix            16         7.9        81.2 
Echinacea purpurea   6         3.0      84.2 
Andrographis paniculata        5          2.5        86.6 
Thymus vulgaris            3          1.5        88.1 
Artemisia vulgaris            2          1.0        89.1 
Calendula officinalis            2          1.0        90.1 
Carica papaya             2          1.0        91.1 
Hamamelis virginiana         2          1.0        92.1 
Matricaria recutita            2          1.0        93.1 
Senna alata             2          1.0        94.1 
Arachis hypogaea            1          0.5        94.6 
Arctostaphylos uva-ursi          1          0.5        95.1 
Arnica montana            1          0.5        95.5 
Atropa belladonna            1          0.5        96.0 
Avena sativa            1          0.5        96.5 
Eucalyptus globulus   1          0.5        97.0 
Melaleuca alternifolia            1          0.5        97.5 
Mentha x piperita            1          0.5        98.0 
Papaver somniferum            1          0.5        98.5 
Pelargonium sidoides           1          0.5        99.0 
Styrax benzoin             1          0.5        99.5 
Symphytum officinale            1          0.5        100.0 
Total            202       100.0 
1Percentage of suspect herbals associated with allergic reactions (n=202) 
 
 
Table 10 Reported suspect herbal associated with asthma-like reactions (n=20) 
Suspect herbal   Frequency    Percent %1      Cumulative % 




Phleum pratense           4         20.0        90.0 
Artemisia vulgaris            1          5.0        95.0 
Thymus vulgaris            1          5.0        100.0 
Total            20        100.0 
1Percentage of suspect herbals associated with asthma-like reactions (n=20) 
  
Of 137 suspect mixed herbals, 48.2 % were reported as WHO-ART lower base name herbal 
pollen, followed by 8.0 % Pelargonium reniforme root/Pelargonium sidoides root and 7.3 % 
Elettaria cardamomum oil/Zingiber officinale extract/ Capsicum annuum	  (Table 11).         
 
Table 11 Preferred base name of suspect mixed herbals 
Suspect mixed herbal    Frequency    Percent %1      Cumulative % 
Herbal pollen nos             66         48.2        48.2 
Pelargonium reniforme root/   11         8.0        56.2 
Pelargonium sidoides root         
Elettaria cardamomum oil/   10         7.3        63.5 
Zingiber officinale extract/ 
Capsicum annuum           
Alnus glutinosa pollen extract/  7          5.1        68.6 
Betula pendula pollen extract/ 
Corylus avellana pollen extract 
Phleum pratense/    7          5.1        73.7 
Dactylis glomerata/ 
Anthoxanthum odoratum/ 
Lolium perenne/Poa pratensis 
Hedera helix leaf/Coptis spp. rhizome           4          2.9        76.6 
Primula veris root extract/   4          2.9        79.6 
Thymus vulgaris herb extract/ 
Hedera helix leaf extract 
Chelidonium majus herb/   3          2.2        81.8 
Melissa officinalis leaf/ 
Silybum marianum fruit/ 
Angelica archangelica root/ 
Carum carvi fruit/ 
Glycyrrhiza glabra root/ 
Matricaria recutita flower/ 
Mentha x piperita leaf/ 
Iberis amara 
Mentha x piperita oil/    3          2.2        83.9 
Ulmus rubra bark powder 




Scutellaria baicalensis root/ 
Salix alba stem bark/ 
Armoracia rusticana root 
Thymus vulgaris extract/   3          2.2        88.3 
Drosera rotundifolia extract 
Aloe vera gum/Aloe ferox gum            2          1.5        89.8 
Panax ginseng root/    2          1.5        91.2 
Schisandra chinensis fruit 
Pinus mugo oil/    2          1.5        92.7 
Eucalyptus globulus oil/ 
Pinus nigra oil 
Alnus glutinosa pollen extract/  1          0.7        93.4 
Betula pendula pollen extract/ 
Corylus avellana pollen extract 
Althaea officinalis extract/   1          0.7        94.2 
Matricaria recutita extract/ 
Equisetum arvense extract/ 
Taraxacum officinale extract/ 
Achillea millefolium extract/ 
Quercus robur extract/ 
Juglans regia extract 
Arachis hypogaea oil/    1          0.7        94.9 
Prunus dulcis oil/ 
Cinnamomum camphora oil 
Cocos nucifera oil/Illicium verum oil/ 1         0.7        95.6 
Cananga odorata flower oil 







Ferula assa-foetida/    1          0.7        97.1  
Rhamnus purshiana dry extract/ 
Strychnos nux-vomica extract/ 
Zingiber officinale rhizome 
Primula veris root extract/ 
Thymus vulgaris herb extract/  1          0.7        97.8 
Hedera helix leaf extract 
Lavandula angustifolia oil/   1          0.7        98.5 
Eucalyptus globulus oil/ 




Cupressus sempervirens oil/ 
Hyssopus officinalis oil 
Pinus mugo oil/    1          0.7        99.3 
Eucalyptus globulus oil/ 
Pinus nigra oil/ 
Pinus sylvestris 
Spirulina spp.              1          0.7        100.0 
Total              137       100.0 
1Percentage of mixed herbal preparations for 137 reported ADRs 
 
6.8 Reporter qualification  
The category physician was the most frequent reporter qualification and was selected in 72 % 
of all cases. Pharmacists are the second most important group (Table 12). 
Table 12 Case reports by reporter type (n=150) 
Reporter qualification    Frequency    Percent %1      Cumulative % 
Physician2     108  72.0  72.0 
Pharmacist              13         8.7        80.7 
Other                8          5.3        86.0 
Other Health Professional             7          4.7        90.7 
Not Converted              5          3.3        94.0 
NULL                4          2.7        96.7 
Manufacturer               3          2.0        98.7 
Nurse                1          0.7        99.4 
Consumer/Non Health Professional            1          0.7         100.0 
Total              150       100.0 
1 Percentage of total number of reports (n=150) by reporter type 
2 The reporter types “General practitioner”, “Hospital”, “Physician” and “Specialist physician” as originally reported in 
VigiBase® were summarized as reporter type “Physician”  
 
6.9 Reaction outcomes 
At the time of reporting, most cases had an outcome where recovery of the patient from one 
or more ADRs was reported (84.7 %); in no case was an ADR to an herbal fatal (Figure 6). 
Of the 9 ADRs reported as “not recovered” rash and urticaria were most common (Table 13) 
caused by various herbals (Table 14). The specific category “anaphylaxis” was most 
commonly associated with mixed herbals and Phleum pratense (Table 15). Of the mixed 





Figure 6 Reaction outcomes (n=222) 
The vast majority of patients were able to fully recover by the time of reporting, 12 patients 
had not yet recovered and 3 developed a chronic condition as a result of exposure to an herbal 
medicine. In no case did a reaction lead to a lethal outcome (Figure 6). 
 
Table 13 ADRs associated with reaction outcome “not recovered” (n=9) 
ADR1   Frequency    Percent %1      Cumulative % 
Urticaria            3         33.3       33.3 
Rash             3         33.3        66.6 
Rash erythematous     1         11.1        77.7 
Bronchospasm           1         11.1        88.8 
Angioedema            1         11.1        100.0 
Total            9        100.0 
1 WHO-ART preferred term name 
 
The most frequent reactions associated with an outcome classified as “not recovered” were 
rash and urticaria (Table 13). 
 
Table 14 Herbals associated with reaction outcome “not recovered” (n=9) 
Herbal1     Frequency    Percent %1      Cumulative % 
Andrographis paniculata             2         22.2        22.2 
Panax ginseng root/Schisandra chinens..       2         22.2        44.4 
Hedera helix               1         11.1        55.5 
Elettaria cardamomum oil/Zingiber off..        1         11.1        66.6 




Pelargonium reniforme root/Pelargoniu..      1         11.1        88.8 
Pinus mugo oil/Eucalyptus globulus oi..       1         11.1       100.0 
Total                9        100.0 
1 WHO-ART preferred base name 
 
In 4 of the 6 cases reported with an outcome as “not recovered” two were caused by 
Andrographis paniculata and two by Panax ginseng/ Schisandra chinensis (Table 14). 
 
Table 15 Herbals associated with anaphylaxis (n=48) 
Herbal1     Frequency    Percent %      Cumulative % 
Mixed herbals              38         79.2        79.2 
Phleum pratense              5         10.4        89.6 
Andrographis paniculata            1          2.1        91.7 
Arachis hypogaea              1          2.1         93.8 
Arnica montana              1          2.1        95.8 
Artemisia vulgaris              1          2.1        97.9 
Hedera helix               1          2.1        100.0 
Total               48        100.0 
1 WHO-ART high level name 
The WHO-ART term mixed herbals was associated with the majority of cases reporting 
anaphylaxis (Table 15).  
Table 16 Mixed herbals associated with anaphylaxis (n=38) 
Herbal1     Frequency    Percent %      Cumulative % 
Herbal pollen nos             31         81.6        81.6 
Alnus glutinosa pollen extract/Betula..           4         10.5        92.1 
Primula veris root extract/Thymus vul..        1          2.6        94.7 
Sambucus nigra flower/Scutellaria bai..         1          2.6       97.4 
Spirulina spp.               1          2.6        100.0 
Total               38        100.0 
1 WHO-ART preferred base name 
 
Of the mixed herbals, herbal pollen nos (not otherwise specified) was the most frequently 
reported term followed by Alnus glutinosa pollen extract/ Betula pendula pollen extract/ 






6.10 Case example 1 
Our initial VigiBase® data set contained 68 variables per case in total plus 7 variables 
generated during analysis with Stata® data analysis and statistical software. Table 17 shows a 
good example of an ICSR where the minimum requirement of information was provided by 
the reporter but several details that could have allowed for a more precise causality 
assessment were lacking.  
The case concerns a 2 year-old girl in Australia who was given an extract of 
Echinacea purpurea and subsequently developed facial oedema. The causality was assessed 
as possible i.e. a plausible temporal relationship between the use of the herbal preparation and 
the occurrence of the ADR were present. If a dechallenge or rechallenge occurred is 
unknown, which therefore excludes the causality assessment options probable or certain. The 
start date of the ADR was April 6th 1999, and the case was first entered into the Australian 
pharmacovigilance database on November 22nd 1999. This illustrates the previously 
discussed problem of information delay within spontaneous reporting systems (SRSs). 
Resolution date and outcome were also not specified, however, facial oedema is not a chronic 
condition and abatement of the symptoms upon withdrawal of the herbal extract or with 
medical treatment would be expected, all the more because the reaction was not classified as 
serious. Route of administration was also not specified and we do not know what the 
indication was. Amount of the extract that was administered is also unknown. This would be 
of particular interest since dosages for children can vary greatly from those used for adults, 
and ADRs can be coded as accidental or deliberate overdose in Vigiflow®. The reporter of the 
reaction was a general practitioner, which falls under the group physicians in our results and 
also constitutes the largest reporter group. Overall, the report presents a rather common ADR 
associated with a commonly used herbal and the occurrence of allergic reactions due to 
Echinacea purpurea has been described before [71]. 
 
Table 17  Raw data ICSR example 1     





























































































PreferredBaseName Echinacea purpurea 
herbal012* 
1 

































    
*	  Categories	  created	  during	  Stata®	  analysis	  
 
6.11 Case example 2 
The second case example concerns a 17 year-old girl who suffered from an immediate type 
hypersensitivity reaction grade IV (WHO preferred term anaphylactic shock) after a single 
oral administration of Arachis hypogaea (peanut) oil. Information for several variables such 
as seriousness, notifier type and amount taken are missing. However, the case still meets the 
specified minimum requirements for ICSRs that are report ID, reporter, patient, suspect 
medicine and ADR [72]. In this case the causality was classified as probable i.e. indicating a 
plausible temporal relationship as well as a “positive dechallenge” (symptoms resolved after 
discontinuation of the peanut oil). Date of onset was May 9th 2000 and the outcome was 
reported as recovered (Table 18).  
In Western countries the number of children affected by peanut allergy has doubled in 
the last decade and is the most frequent cause of anaphylaxis and death associated with food 
allergies [73]. Compared to milk and egg allergy, only few children outgrow their peanut 
allergy and 1-2 % of children in the UK are thought to be affected [74]. 
 
Table 18 Raw data ICSR example 2 
Variable Result Variable Result 
Report_id 2644331 AmountCode - 
DateDatabase 20010821 AmountUnit NULL 
FirstDateDatabase 20010821 Frequency 1 
CountryCode NZL FrequencyCode 10 
CountryText New Zealand FrequncyUnit Time(s) 
SafetyReportId NZ-NZNC-044334 RouteCode PO 
CompanyNumb - Route Oral 
Serious - IndicationSupText NULL 
Seriousness NULL IndicationText NULL 











NotifierTypeCode - ReactionSeriousness - 
NotifierType NULL WhoArtSocCode 1810 
AgeReaction 17 WhoArtArecno 713 
agereacnum 17 WhoArtSeq 2 
AgeU 
6 WhoArtSOC_name 














Gender Female CausalityCode 2 
ReOutcome Recovered Causality Probable 
onsetdate2 ######## Dechallenge1 1 
OnsetDate 20000509 DechallengeAction Drug withdrawn 
ResolutionDate - Dechallenge2 1 
MedProd_ID 33779 DechallengeOutcome Reaction abated 
ReportedDrug ARACHIS OIL Rechallenge1 3 
MAH 0 RechallengeAction No rechallenge 
MAHolder None Rechallenge2 4 
PreferredBase 1646801 RechallengeOutcome Not applicable 
PreferredBaseName Arachis hypogaea herbal012* 1 
herb_highlev_name Arachis hypogaea adrcat012* 1 
PreferredSalt 1646802 jitkaadrcat012* 1 
PreferredSaltName Arachis hypogaea oil ADRtype* 1 
BasisCode 1 Latencytime* 0 
Basis Suspect lattime3cat* 1 
startdate2 ######## Anaphylaxis* 1 
StartDate 20000509   
StopDate 20000509   
Amount -   
    











This descriptive study analyzed a VigiBase® extract from 1960 to August 2014 and is the first 
study to report global ADR data associated with hypersensitivity reactions due to herbal 
medicines in children. A comparatively small number of ICSRs, namely 0.09 % of the 
original data set, were associated with herbal induced hypersensitivity reactions in pediatric 
patients under the age of 18. The initial data set containing 26,909 ICSRs related to herbals 
represent roughly 0.27 % of over 10 million reports that have been reported in VigiBase® to 
this date [31]. In 1999, the UMC database reached 2 million reports of which 0.5 % were 
related to herbals [75]. However, this decrease in percentage of herbal reports contributing to 
the entire database does not reflect a decrease in herbal medicine use. In 1999, the WHO 
international pharmacovigilance program counted far less member countries than the current 
120 permanent and 29 associate members as of December 2014 [29, 30]. Quite the opposite 
holds true and herbal medicine use has consistently been increasing worldwide as has the 
total number of herbal ADR reports. Hence, an overall a faster increase in the number of 
reported ADRs due to conventional medicines than herbals could explain this 
disproportionality. The growing global popularity of herbal use was also reflected in our 
study by the increasing number of reports from 1986 until 2011. However, increased number 
of member countries as well as possible policy changes regarding herbal medicines in some 
countries and increased awareness of their health risks may have influenced reporting over 
the years. We currently do not have an explanation for the decrease in number of reports in 
this study after 2011. It has been shown that the rate at which an ADR is reported can vary 
among drugs and can change for the same drug over a period of time [32].  
Regarding gender distribution, overall evidence is contradictory with some studies 
reporting higher percentages of ADRs occurring in male pediatric patients [34, 67, 76, 77] 
even though female pediatric and adolescent patients use more complementary and 
alternative medicines including herbals [13, 78]. Our study results showed 54 % of pediatric 
patients affected by ADRs were male, which agrees with previous studies [34, 67, 76, 77, 
79].  However, these studies mainly discussed the overall ADR incidence in children, without 
a focus on herbals or hypersensitivity reactions. Whether this is an actual indication that male 
pediatric patients suffer more frequently from hypersensitivity reactions than girls, or simply 
that more reports concerning boys than girls are submitted, remains unclear at this point. 
However, it has previously been reported that boys seem to be at a higher risk of suffering 




allergies and anaphylaxis once puberty is reached and sex hormones are thought to play a role 
in this change in prevalence [80]. 
In our study urticaria was the most frequently reported ADR (22.1 %) in children 
using an herbal medicine and who were under the age 18. This is consistent with a previous 
study by Jacobsson et al. where all ICSRs with at least one suspect complementary and 
alternative medicine (CAM) reported to the Swedish Medical Products Agency between 1987 
and 2006 were analyzed [44]. Here urticaria was reported as the most common ADR (8.3 %), 
followed by exanthema (7.4 %) and contact dermatitis (5.7 %). On the other hand, an 
anaphylactic reaction was reported in 7.2 % of all cases in our study whereas Jacobsson et al. 
reported anaphylaxis in 2.0 % of all cases. Their study however did not focus on pediatric 
patients but analyzed 778 cases of ADRs related to CAM products with an average patient 
age of 53 years. A study by Kimland et al. found that between 1987 and 2001 46 % of all 
ADRs in children under the age of 18 were skin related. Of these 24 % accounted for 
application site reactions, 12 % fever, 6.7 % exanthema and 6.2 % for urticaria [43]. In our 
study, urticaria was the most commonly coded WHO-ART preferred term (22.1 %), followed 
by rash (11.7 %) and anaphylactoid reaction (9.0 %). This could suggest that the skin is the 
most common organ system affected by adverse drug reactions in general in children and 
adolescents or for herbal medicine use independent of patient age.  
The most common reported suspect herbal was coded with the WHO-ART preferred 
term “mixed herbal” (60.9 %). Herbal pollen nos (not otherwise specified) constituted the 
majority of mixed herbals with 48.2 %. Herbal pollen are commonly used for subcutaneous 
or sublingual allergen-specific immunotherapy to treat allergic rhinitis, which if left 
untreated, can develop into asthma [81]. Allergic rhinitis with or without conjunctivitis is one 
of the most common hypersensitivity reactions in pediatric patients. About 40 % of children 
are thought to be affected [82, 83]. This explains the high percentage of reports being 
associated with herbal pollen (see case example 1). However, it is known that a history of 
allergy is a risk factor for suffering from anaphylactic reactions and severe anaphylaxis [84]. 
Our study did not further analyze route of administration but intravenous injections logically 
pose the greatest risk of inducing severe allergic reactions and anaphylaxis due to immediate 
systemic absorption. A Chinese study showed that in 2013, 17.3 % of all ADR reports in 
China were related to TCM, with over 70% of all serious reports ocurring when an 
intravenous route of administration was used [21]. 
Reports in VigiBase® indicative of hypersensitivity reactions and even circulatory 




[85] and agree with the results found in our study where P. reniforme root/ P. sidoides root 
was the second most frequently reported mixed herbal, accounting for ADRs in 8 % of all 
cases. Timmer et al. describe in their Cochrane review that the root of P. reniforme and P. 
sidoides is used in various dosage forms such as syrups, tablets and ethanolic solutions for the 
treatment of acute respiratory infections and known under brand names such as 
Umckaloabo®, a particularly popular herbal preparation in Germany used to treat bronchitis 
in children. However, the Cochrane review concluded that the overall evidence for 
P.reniforme and P. sidoides root was either low or very low for different respiratory tract 
infections in adults and children [86].  
Out of all herbal drugs, the second  and third most frequently reported herbal 
preparation leading to allergic as well as asthma-like symptoms were Phleum pratense 
(13.1 %) and Hedera helix (7.2 %). P. pratense, also known as Timothy grass, and its pollen 
are common aeroallergens causing allergic rhinitis with or without conjunctivitis [87, 88]. 
Subcutaneous and sublingual forms of allergen specific immunotherapy (SLIT) are available 
for various grasses such as Thimothy grass but serious side effects and anaphylaxis have been 
reported before [89]. H. helix, known as the common Ivy, has antitussive properties and has 
traditionally been used to treat various respiratory diseases but solid evidence of its 
usefulness is still lacking [90]. It is known that H. helix can cause occupational contact 
dermatitis and asthma [91]. 
For all other single suspect herbals found in this study, with the exception of Senna 
alata, Arctostaphylos uva-ursi, Atropa belladonna and Symphytum officinale,                            
hypersensitivity reactions have been reported previously. A study by Suwankesawong et al. 
analyzed a Thai Vigibase® extract from February 2001 to December 2012 and found 106 
cases in which Andrographis paniculata was the suspect herbal and caused at least one ADR 
indicative of a hypersensitivity reaction, with anaphylactic shock being reported in five cases 
and anaphylactic reaction in 4 cases [92]. A case study by Benito et al. described the 
occurrence of facial edema, respiratory difficulties and pruritus after ingesting food seasoned 
with thyme or oregano; ingestion of the same foods without the herbs caused no symptoms 
[93]. A study by Kurzen et al. describes the case of a florist who suffered from life-
threatening glottal oedema after working with Artemisia vulgaris [94] and a report of 
anaphylactic shock after gargling with an infusion of Calendula officinalis exists in the 
literature [95]. Carica papaya is known to be a food allergen and to cause immediate 
hypersensitivity reactions [96]. Reactions to witch hazel, Hamamelis virginiana are rather 




reaction in an 8-year-old boy after drinking a tea containing Matricaria recutita exists in the 
literature [98]. Another of the more common herbals causing allergic reactions is Arnica 
montana [99]. Documentation regarding anaphylaxis due to the common oat, Avena sativa, is 
sparse but a case report of a 7-year-old boy who developed cough, pruritus, and wheezing 
after consuming oats exists in the literature [100].  Allergic contact dermatitis caused by 
Eucalyptus globulus has been reported [101] and hypersensitivity reactions are known to 
occur with Melaleuca alternifolia (Tea tree) [102]. A case study describing anaphylaxis due 
to Mentha piperita can be found in the literature [103] and IgE mediated allergic reactions 
have been documented for Papaver somniferum [104]. Contact allergy for Styrax benzoin has 
also been reported previously [105]. 
The majority of ADRs in our study concerned either the skin or hypersensitivity 
reactions, with urticaria (22.1 %), rash (11.7 %) and anaphylactoid reaction (9.0 %) 
accounting for the majority of reported ADRs. This is largely consistent with previous studies 
that investigated ADRs to herbals in adults and pediatric patients due to complementary and 
alternative medicines which include herbals [44, 106]. Most studies investigating ADRs in 
children have focused on conventional medicines. However, even in those studies the skin 
was reported to be the most commonly affected organ system followed by the gastrointestinal 
tract [43, 66, 107].  
In our study the occurrence of ADRs was highest in those age 13-17. It has been 
shown before that children and teenagers may be more prone to suffer from hypersensitivity 
reactions than the rest of the population [108]. We did not further analyze reports by age 
group and country of origin, however, the majority of reports came from Germany (n=42), a 
country with a long history and tradition of herbal and homeopathic medicine use. The 
German health care system covers herbal remedies for children under 12 years of age [78]. In 
our study 92 of 150 cases occurred in children 0-12 years. Use of herbal medicines in this age 
group due to insurance coverage may pose an incentive for German parents to choose 
alternative medicine options for their underage children. However, we do not know in how 
far this is reflected in the age group to country of origin relationship in our study and further 
investigations would be necessary. Apart from Germany, Sweden has also been a member 
country of the WHO Program for International Drug Monitoring (PIDM) since its start in 
1968, and contributed the second highest number of reports in our study. Thailand was the 
third most significant contributor and has been one of the most actively participating new 




As reported in previous studies [34, 44], the largest group of reporter type in our study 
were physicians, followed by pharmacists. A review by Inch et al. showed that generally 
more reports are submitted by female physicians and that pharmacists report substantially less 
than physicians [109]. On the other hand, in a Portuguese study by Inácio et al., that analyzed 
reporter types in a region in the South of Portugal in 2004 and 2012, pharmacists were the 
main contributors of ADR reports, followed by hospital pharmacists [110]. This reflects the 
ongoing shift away from doctors being the primary reporters of ADRs as has been the case 
since the start of the WHO’s PIDM in the 1960’s [20]. Yet another study found that of 2437 
reports reported to the Danish Medicines Agency between 1998 and 2007, 90 % of all reports 
were reported by physicians however, they only reported equally as many serious ADRs as 
consumer whereas other health care professionals and consumers were more likely to report 
serious ADRs [111]. Since we do not know if any of the physicians who reported the ADRs 
in this study are allergist or CAM specialists, it is not clear in how far reporter type might 
confound the data.  
Apart from the important contribution health care professionals have in 
pharmacovigilance, there is a growing understanding of the role that patients and consumers 
play in post-marketing surveillance of conventional and herbal medicines. Now required by 
law in the EU, consumer reporting was already practiced in Sweden and the Netherland long 
before the law was implemented and results show that it has been a highly valuable tool in 
signal detection [112]. However, most countries still need to significantly increase the 
public’s awareness of the possibility to report ADRs, considering that patient reports have 
been found to be an invaluable source of pharmacovigilance data [113].  
Despite the various limitations spontaneous reporting as a means of post-marketing 
surveillance has, the importance of SRSs in ADR detection has been acknowledged widely 
[25].  The main drawbacks of using SRS’s as a source for pharmacovigilance data remains 
the problem of underreporting, duplicate reports, a certain background incidence of a 
particular ADR in the population and unknown exposure of a patient to a drug [21]. Some 
studies found that under-reporting for non-serious ADRs is even greater than for serious 
ADRs, leading to only 4 % of non-serious and 10 % of serious ADRs being reported [24, 
114, 115], which most likely extrapolates to even greater numbers for herbal medicines. In 
our study 36 % of ADRs (n=80) related to hypersensitivity were reported as serious. Even 
though we did not further analyze them, the main confounders of this study are potential co-
medications and co-morbidities. For now the number of cases that have been affected by 




be done. In addition, other than for the 39 cases with a certain causality assessment where a 
“positive re-challenge” had occurred, a definite correlation between the suspect herbal and 
reported ADRs cannot be assumed. Cases with a probable and possible causality may be 
highly suggestive of a relationship between the suspect herbal and ADR(s) but do not 
represent certain evidence. Likewise factors such as insect bites, increased exercise regimen, 
mastocytosis, uncontrolled asthma, food hypersensitivities or latex allergy may have 
confounded the data [108]. Semantics have also been shown to influence ADR selection of 
MedDRA reaction terms by reporters used to code an adverse event [110] and the same may 
be presumed for WHO-ART, which was used in this study. Another limitation might have 
been the manual selection process of reaction terms that indicate hypersensitivity and the 
overall exclusion of all GIT related symptoms. Since food allergies often cause 
gastrointestinal symptoms that can be either IgE-mediated, non-IgE mediated or mixed IgE 
and non-IgE mediated [116], we decided to exclude GIT symptoms from the list of selected 
reaction terms altogether. Other symptoms such as cough, dyspnoea, larynx pain and pruritus 
ani or genital were excluded from the reaction terms as the probability of a non-herbal related 















This descriptive study was the first study to analyze the worldwide occurrence of 
hypersensitivity reactions in children associated with herbal medicines as reported in 
VigiBase®. Results highlighted the potential of herbals to cause serious allergic reactions in 
children. Herbal medicines were shown not to be “safe” as perceived by many parents and 
consumers worldwide. The global increase in herbal medicine use calls for improved, 
standardized and more consistent reporting of ADRs associated with herbals to ultimately 
provide safer treatment options for children and adolescents. Due to the lack of clinical 
studies in pediatrics for both conventional and herbal medicines, it is also important to realize 
the potential of pharmacovigilance data as a tool in signal detection for pediatric patients and 
improvements at all levels of the pharmacovigilance process need to be made. Reporting rate 
and awareness of the public and medical staff of the importance of pharmacovigilance needs 
to be increased. Ultimately, the small number of cases included in this study make any 
generalizations or pharmacoepidemiologic conclusions about the results infeasible. It should 
be noted that the ICSRs that comprised the data extract used for this study came from a 
variety of sources and the likelihood that the suspected adverse reactions are drug-related is 
not the same in all cases. This study focused on the occurrence of ADRs indicative of 
hypersensitivity in patients under 18 years of age only. Further studies need to be conducted 
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11 Czech Abstract 
Úvod: Spotřeba bylinných přípravků neustále vzrůstá jak mezi dospělými, tak mezi dětmi. 
Na bylinné přípravky je často nahlíženo jako na bezpečnou alternativu ke klasické léčbě, 
ačkoliv i bylinné přípravky mohou způsobovat různé nežádoucí účinky včetně závažných a 
smrtelných alergických reakcí. Prevalence celoživotního užívání bylinných přípravků u dětí 
se pohybuje mezi 0.8–85.5 % a 2.2–8.9 %. Na rozdíl od syntetických léčiv se nežádoucí 
účinky u bylinných přípravků studují zřídka. V současnosti neexistují účinné systémy, jakými 
by se tyto nežádoucí účinky včetně dlouhodobých účinků efektivně monitorovaly, popřípadě 
se v řadě zemích tyto systémy budují. Vzhledem k nedostatečnému a nekonzistentnímu 
monitorování nežádoucích účinků bylinných přípravků u dětí, toho o nich není moc známo. 
Povědomí o nežádoucích účincích bylinných přípravků u dětí by se mělo zvyšovat a jejich 
hlášení do farmakovigilačních center podporovat.                  
Cíl: V rámci studie jsme analyzovali nežádoucí účinky bylinných přípravků u dětí do 18 let 
týkající se hypersenzitivních reakcí hlášených do databáze Světové zdravotnické organizace 
VigiBase® v letech 1968 – srpen, 2014.                                                                        
Metody: Do studie byly zahrnuty všechna spontánní hlášení z VigiBase® obsahující HATC 
kód, s klasifikací „podezřelé“, s hodnocením kauzality „jistá, možná, pravděpodobná“, s 
nástupem nežádoucího účinku 0-1 den, s pacienty mladšími 18 let, s nežádoucími účinky 
naznačujícími hypersenzitivní reakci. WHO-ART terminologie naznačující alergie byly dále 
rozděleny na nežádoucí účinky podobné alergii a nežádoucí účinky podobné astmatu. 
Výsledky: Celosvětově bylo hlášeno 26,909 případů týkajících se nežádoucích účinků 
bylinných přípravků a 237,496 nežádoucích účinků. Z těchto dat, 150 případů s 222 
nežádoucími účinky splňovaly vstupní kritéria studie. Z 222 nežádoucích účinků, bylo 202 
klasifikovaných jako nežádoucí účinky podobné alergii a 20 jako nežádoucí účinky podobné 
astmatu. Mezi nejčastěji hlášené WHO-ART termíny vztahující se k nežádoucím účinkům 
podobným alergii byly urtikarie (22.1 %), vyrážka (11.7 %) a anafylaktoidní reakce (9.0 %). 
Mezi nejčastější nežádoucí účinky podobné astmatu patřily astma (5.4%) a bronchospasmus 
(2.7 %). Nežádoucí účinky podobné alergii (60.9 %) a astmatu (70.0 %) byly nejčastěji 
způsobeny bylinnými směsi. Anafylaktický šok byl reportován ve 12 případech (5.4%) a 
v žádném případě nedošlo ke smrti. Většina hlášení nežádoucích účinků spadala do věkové 




Nežádoucí účinky se vyskytovaly více u chlapců (54 %) nežli u dívek (46 %). Většina hlášení 
pocházela z Německa (28 %), Švédska (15.3 %) a Thajska (11.3 %).           
Závěr: Data analyzována z Vigibase ukázala, že bylinné přípravky mohou vést k závažným 
hypersenzitivním reakcím a anafylaxi u dětí a dospívajících. Je potřeba zvýšit povědomí o 
potenciálním riziku spojeným s užíváním bylinných přípravků a podpořit jejich hlášení 
z důvodu lepší využitelnosti dat v rámci farmakovigilance.  
 
